US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

82.20

+5.777.55%

Post-market: 82.200.00000.00%19:45 EST

Volume:396.37K

Turnover:32.60M

Market Cap:972.96M

PE:-23.29

High:85.05

Open:78.93

Low:78.93

Close:76.43

52wk High:114.69

52wk Low:14.68

Shares:11.84M

Float Shares:7.16M

Volume Ratio:1.03

T/O Rate:5.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.5291

EPS(LYR):-7.8322

ROE:-301.19%

ROA:-47.54%

PB:25.15

PE(LYR):-10.50

Loading ...

Overview Company News Filings

Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright

Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating

Palvella Therapeutics management to meet virtually with Craig-Hallum

Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis

Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133

THOMSON REUTERS

Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

Palvella Therapeutics (PVLA) Receives a Buy from BTIG

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics

BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward

BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook

Palvella Therapeutics issues update, 2026 outlook

Palvella Therapeutics Files Patent for QTORIN™ Pitavastatin Program, Expanding Potential Exclusivity Through 2046

Palvella Therapeutics Inc - Phase 2 Clinical Studies for Qtorin™ to Start in H2 2026

THOMSON REUTERS

Palvella Therapeutics Inc - Nda Submission Planned for Second Half of 2026

THOMSON REUTERS

Palvella Therapeutics Inc - Phase 3 Selva Study Results Expected in March 2026

THOMSON REUTERS

Palvella Therapeutics Inc - Requested Breakthrough Therapy Designation Meeting With FDA in Q1 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":82.2,"timestamp":1770411600000,"preClose":76.43,"halted":0,"volume":396365,"hourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":82.2,"latestTime":"19:45 EST","volume":1317,"amount":108279.34,"timestamp":1770425107894,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07549391600157,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"Market Closed","change":5.77,"latestTime":"02-06 16:00:00 EST","open":78.93,"high":85.045,"low":78.93,"amount":32604675.7353,"amplitude":0.080008,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":76.43,"preHourTrading":{"tag":"盘前","latestPrice":78.49,"preClose":76.43,"latestTime":"08:46 EST","volume":2,"amount":156.98999,"timestamp":1770385565702,"change":2.06,"changeRate":0.026953,"amplitude":0.000131},"postHourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":82.2,"latestTime":"19:45 EST","volume":1317,"amount":108279.34,"timestamp":1770425107894,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0324672411608795,"optionData":{"bulkOrders":[{"symbol":"PVLA","call":true,"expireDate":1771563600000,"strike":"110.0","timestamp":1770389734166,"price":0.8,"volume":1500,"amount":120000,"type":"-"}]},"impliedVol":1.8307,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":7158500,"roa":"-47.54%","roe":"-301.19%","lyrEps":-7.832217,"volumeRatio":1.0324672411608795,"shares":11836490,"dividePrice":0,"high":85.045,"amplitude":0.080008,"preClose":76.43,"low":78.93,"week52Low":14.68,"pbRate":"25.15","week52High":114.69,"institutionHeld":0,"latestPrice":82.2,"eps":-3.529122,"divideRate":0,"volume":396365,"delay":0,"ttmEps":-3.529122,"open":78.93,"prevYearClose":104.67,"prevWeekClose":76.69,"prevMonthClose":76.69,"prevQuarterClose":104.67,"fiveDayClose":76.69,"twentyDayClose":97.38,"sixtyDayClose":80.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1767848400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-02-06","current":-23.291912,"percent":0.280702,"low":-39.17838,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"high":46.119317,"avg":-9.935429,"sd":23.721987,"marketCap":904662930},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930}],"updateTime":1770543522661},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608874070","title":"Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874070?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:58","pubTimestamp":1770127087,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Palvella Therapeutics, with a price target of $200.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2608892765","title":"Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2608892765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608892765?lang=en_us&edition=fundamental","pubTime":"2026-02-03 03:25","pubTimestamp":1770060354,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics and keeping the price target at $150.00. Sam Slutsky has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-pvla-mechanistic-validation-unmet-need-and-pivotal-trial-catalysts-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-pvla-mechanistic-validation-unmet-need-and-pivotal-trial-catalysts-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2608898432","title":"Palvella Therapeutics management to meet virtually with Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2608898432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608898432?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:15","pubTimestamp":1770045334,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on February 11 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-virtually-with-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-management-to-meet-virtually-with-craig-hallum-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2608869868","title":"Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869868","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869868?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:30","pubTimestamp":1770035425,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc., a clinical-stage biopharmaceutical company focused on rare skin diseases, announced the publication of a systematic review in Clinical and Experimental Dermatology synthesizing clinical evidence on off-label cutaneous statin use for porokeratosis. The review, which includes 24 studies, highlights persistent treatment gaps due to the lack of FDA-approved therapies for this condition and supports the development of Palvella's QTORIN pitavastatin for disseminated superficial actinic porokeratosis . The company indicated that QTORIN pitavastatin is anticipated to enter Phase 2 clinical development in the second half of 2026. No new clinical study results have been presented; future trials are planned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7TLvX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","PVLA"],"gpt_icon":0},{"id":"2608868869","title":"Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133","url":"https://stock-news.laohu8.com/highlight/detail?id=2608868869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608868869?lang=en_us&edition=fundamental","pubTime":"2026-02-02 18:47","pubTimestamp":1770029252,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2607040536","title":"Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040536?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:10","pubTimestamp":1769789418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR – Research Report), Palvella Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-danaher-dhr-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-danaher-dhr-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU2112291526.USD","LU0689472784.USD","BK4533","LU1923622614.USD","LU1791710582.SGD","LU0320765059.SGD","LU1023059063.AUD","LU0882574055.USD","LU0511384066.AUD","LU2125909593.SGD","BK4581","LU1791710400.SGD","LU2023250504.SGD","LU0390134368.USD","XLV","LU2265009873.SGD","LU0528227936.USD","LU1551013342.USD","LU1804176565.USD","SG9999013999.USD","LU0672654240.SGD","SGXZ23171101.USD","LU1917777945.USD","BK4139","LU2106854487.HKD","PVLA","LU0114720955.EUR","LU1267930730.SGD","BK4504","LU1057294990.SGD","LU0432979614.USD","LU0312595415.SGD","BK4121","LU0157215616.USD","LU0289739343.SGD","LU2125909247.SGD","LU0289961442.SGD","LU1061106388.HKD","IE00BQXX3D17.EUR","DHR","HCSG","XBI","LU0820561909.HKD","BK4137","LU0820561818.USD","LU0097036916.USD","LU0708995401.HKD","LU0109391861.USD","LABU"],"gpt_icon":0},{"id":"2607082134","title":"Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2607082134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607082134?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:43","pubTimestamp":1769690580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 07:43 ET (12:43 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2607084233","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084233?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:20","pubTimestamp":1769689217,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","LABU","BK4533","LU0889565916.HKD","IE00BN0W2V16.EUR","BK4532","BK4137","HCSG","BK4139","LU0320765992.SGD","LU0128526141.USD","LU0154245673.USD","XLV","XBI","PVLA","LU0109394709.USD","JAZZ","NRIX","LU0029874061.USD","BK4588","LU0154245756.USD","BK4581","LU0823416689.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2605143659","title":"Palvella Therapeutics (PVLA) Receives a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2605143659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605143659?lang=en_us&edition=fundamental","pubTime":"2026-01-21 02:06","pubTimestamp":1768932390,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee maintained a Buy rating on Palvella Therapeutics on January 16 and set a price target of $192.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2604918205","title":"Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604918205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604918205?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:36","pubTimestamp":1768584960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 12:36 ET (17:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2603967369","title":"Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603967369?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:20","pubTimestamp":1768569611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","XBI","BK4588","LU0128526141.USD","LU0029874061.USD","BK4139","BK4581","BK4137","LABU","PVLA","BK4112","BK4585"],"gpt_icon":0},{"id":"2603616576","title":"Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616576?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:57","pubTimestamp":1768395440,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $150.00. Sam Slutsky has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/physician-survey-underscores-undervalued-commercial-upside-for-qtorin-topical-rapamycin-supporting-buy-on-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/physician-survey-underscores-undervalued-commercial-upside-for-qtorin-topical-rapamycin-supporting-buy-on-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2602306450","title":"BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2602306450","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602306450?lang=en_us&edition=fundamental","pubTime":"2026-01-10 03:45","pubTimestamp":1767987944,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital mainta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-palvella-therapeutics-de-risked-selva-phase-3-design-positions-qtorin-rapamycin-for-first-in-class-mlm-approval-and-compelling-risk-reward-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-palvella-therapeutics-de-risked-selva-phase-3-design-positions-qtorin-rapamycin-for-first-in-class-mlm-approval-and-compelling-risk-reward-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BUY","MLM"],"gpt_icon":0},{"id":"2602375197","title":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375197?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:55","pubTimestamp":1767963328,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2602375851","title":"Palvella Therapeutics issues update, 2026 outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375851?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:36","pubTimestamp":1767962162,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) provided a corporate update and 2026 strategic outlook on the Company’s late clinical-stage pipeline and QTORIN platfo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issues-update-2026-outlook-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-issues-update-2026-outlook-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2602637342","title":"Palvella Therapeutics Files Patent for QTORIN™ Pitavastatin Program, Expanding Potential Exclusivity Through 2046","url":"https://stock-news.laohu8.com/highlight/detail?id=2602637342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602637342?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961821,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. announced the expansion of its intellectual property portfolio in 2025 with the granting of two U.S. patents for QTORIN rapamycin, covering anhydrous compositions, 0.1-20% mTOR inhibitor formulations, and methods of use for rare skin diseases. These patents strengthen the asset's multi-layered protection through 2038. Additionally, the company filed a patent application for its QTORIN pitavastatin program, which could provide potential exclusivity through 2046.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL2rTZNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","SG9999014039.USD","BK4112","PVLA","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2602637328","title":"Palvella Therapeutics Inc - Phase 2 Clinical Studies for Qtorin™ to Start in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602637328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602637328?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2602404373","title":"Palvella Therapeutics Inc - Nda Submission Planned for Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602404373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602404373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2602373407","title":"Palvella Therapeutics Inc - Phase 3 Selva Study Results Expected in March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373407?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2602373283","title":"Palvella Therapeutics Inc - Requested Breakthrough Therapy Designation Meeting With FDA in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373283?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}]}}